U.S. Markets closed

International Stem Cell Corporation (ISCO)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.32-0.17 (-11.41%)
At close: 3:57PM EDT
People also watch
BTXSCONNNVCCURPSTI

International Stem Cell Corporation

5950 Priestly Drive
Carlsbad, CA 92008
United States
760-940-6383
http://www.internationalstemcell.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees42

Key Executives

NameTitlePayExercisedAge
Prof. Andrey Semechkin Ph.D.Co-Chairman and Chief Exec. Officer143.07kN/A57
Ms. Mahnaz Ebrahimi CPAChief Financial Officer and Sec.187.5kN/A60
Dr. Russell Kern Ph.D.Chief Scientific Officer, Exec. VP and Inside Director196.15kN/A31
Mr. Kenneth C. Aldrich J.D.Co-Founder and Chairman EmeritusN/AN/A78
Ms. Sophia GarnetteVP of Legal Affairs & OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on development of therapeutic and biomedical products worldwide. The company’s products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. It develops cell types, including neural stem cells for the treatment of Parkinson’s disease and other neurological disorders; liver cells to treat various congenital and acquired liver diseases; islet cells for treatment of diabetes; and retinal cells and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company’s human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a branded Website, professional channels, and distributors; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in Carlsbad, California.

Corporate Governance

International Stem Cell Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.